Michael Song

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Kristian Reich, April W. Armstrong, Peter Foley et al. · Journal of the American Academy of Dermatology · 2017 · 712 citations · Full text

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial

Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin et al. · British Journal of Dermatology · 2017 · 336 citations · Full text

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Arthur Kavanaugh, Christopher T. Ritchlin, Proton Rahman et al. · Annals of the Rheumatic Diseases · 2014 · 293 citations · Full text

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

Tsen‐Fang Tsai, Ji‐Chen Ho, Michael Song et al. · Journal of Dermatological Science · 2011 · 210 citations

Autoimmune Disease, Phase Iii, Clinical Trials +7

Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial

Atsuyuki Igarashi, Takeshi Kato, Mai Kato et al. · The Journal of Dermatology · 2011 · 203 citations · Full text